Hemispherx Biopharma buys royalty interest for Alferon N Injection from Stem Cell Innovations

By Lisa Kerner

Charlotte, N.C., Aug. 1 - Hemispherx Biopharma, Inc. said it has purchased the royalty interest related to the sales of its natural alpha interferon products from Stem Cell Innovations, Inc.

Hemispherx acquired Stem Cell's 43,000-square-foot research and manufacturing facility in New Jersey as well as the worldwide license for the production, manufacture, use, marketing and sale of Alferon N Injection in March 2004.

Alferon N Injection is a Food and Drug Administration-approved natural human alfa interferon product for the treatment for human papilloma viruses.

Based in Philadelphia, Hemispherx manufactures and develops new drug entities for treatment of viral and immune-based disorders, including gene-based disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.